ZITHROMAX (azithromycin) by Pfizer is drug. First approved in 1994.
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
ZITHROMAX (azithromycin) is an oral macrolide antibiotic approved in 1994 that disrupts bacterial protein synthesis to treat a broad spectrum of respiratory, skin, and sexually transmitted infections. It is a foundational small-molecule antibiotic with decades of clinical use and established safety profiles across diverse patient populations.
Product approaching loss of exclusivity with moderate competitive pressure (30%); expect portfolio transition focus and consolidation of legacy-stage commercial teams.
drug. [see Microbiology ()]
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Azithromycin Prophylaxis for PRElabor CEsarean DElivery Trial
Azithromycin as Adjunctive Treatment for Uncomplicated Severe Acute Malnutrition
Erythromycin Versus Azithromycin for Preterm Prelabor Rupture of Membranes
Optimising Azithromycin Prevention Treatment in COPD to Reduce Exacerbations
Azithromycin Before Induction
Worked on ZITHROMAX at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on ZITHROMAX offers limited growth trajectory as a mature, generic-competitive asset approaching LOE; roles focus on portfolio optimization, cost management, and market defense. Career value lies in demonstrating excellence in legacy product stewardship rather than innovation-driven advancement.